TTC-LLC-Research
Dr. Harold E. Glass

Research

Dr. Harold E. Glass is one of the leading industry experts in drug development costs.  He has been extensively published in industry magazines and peer review journals on a wide range of drug development topics, in addition to drug development cost management.


Site-Cost Line Item Charges on the Rise. Glass H. Applied Clinical Trials, Vol. 21, No. 10, pp. 18, October 2012
Standard of Care Billing More Widespread. Glass L. Applied Clinical Trials, Vol. 21, No. 6, pp. 16, June 2012
Grants Still Most Expensive in the United States. Glass L. Applied Clinical Trials, Vol. 21, No. 3, pp. 18, March 2012
Clinical Grant Expenditures are Stabilizing. Glass L. Applied Clinical Trials, Vol. 20, No. 11, pp. 20, November 2011
How Much Are CROs Actually Used? Glass H. Inside Outsourcing, pp.44-50. November 2011
Find Savings Through SOC, Glass H. SCRIP Clinical Research. September 2011
Latin America Research Stats, Glass H. Applied Clinical Trials, Vol. 20, No. 8, pp. 16, August 2011
Latin American Physician’s Attitudes Toward Participation in Clinical Trials, Glass H. and Glass J., Pharmaceutical Medicine, Vol. 25, No. 2, pp. 87-94, 2011.
Controlling Costs of Clinical Trials in Oncology. Glass H & Poli L. FOCUS. pp 22-27. February 2011.
Investigator insights; CRO or sponsor preference? Glass H. Scrip Clinical Research. pp 16-17 December 2010.
Clinical Grant Expenditures are on the Rise Throughout the World, Glass H. Applied Clinical Trials, Vol. 19, No. 10, pp. 14, October 2010.
Standard Of Care In Study Budgeting. Glass H. Applied Clinical Trials. pp 36-42. Vol. 19, No 7. July 2010.
Do Sites Prefer a Sponsor Company or a CRO to Run Their Clinical Trial? Glass H. Applied Clinical Trials. pp 14. Vol. 19, No 7. July 2012
Two Worlds, One Planet. Glass H. Inside Outsourcing. pp 46-52. November 2009.
Managing Clinical Grant Costs. Glass H & Hollander K. Contemporary Clinical Trials. October 2009.
What Bothers Clinical Investigators. Glass H. Good Clinical Practice Journal. pp 21-23. July 2009.
Reporting Concerns. Glass H. Applied Clinical Trials. pp 14. Vol.18. No 7. July 2009.
CRO Selection & Management. Glass H & Beaudry D. Applied Clinical Trials. April 2009.
The World’s Your Clinical Research Oyster. Glass H. Scrip Magazine. April 2009.
Refutable Rates. Glass H. Applied Clinical Trials. pp 14. April 2009.
Study Conduct a Big Part of the Budget. Glass H. Applied Clinical Trials. pp 14. January 2009.
Investigator Attitudes toward Participation in Contract Research Organization-Managed Clinical Studies: A Survey of US Clinical Investigators. Glass H. Pharmaceutical Medicine. 23 (2): pp 85-90. 2009.
Investigator Dissatisfaction with the Conduct of Clinical Trials. Glass H. The Monitor. 23(4): pp 58-62. 2009.
Pressure Points on Industry Executives: What Lies Ahead? Glass H & Poli L. International Journal of Pharmaceutical and Healthcare Marketing. Vol. 3, Iss. 1. 2009.
The profile of the one-time 1572 investigator. Glass H. Contemporary Clinical Trials. Vol. 30, pp 34-39. 2009. 
The Importance of Medical Innovation in an Investigator's Decision to Take Part in Clinical Trials. Glass H. Drug Information Journal. pp 537-543. Vol 42, March 2008.
Key Factors in CRO Selection. Glass H & Beaudry D. Applied Clinical Trials. April 2008.
Connecting the Dots. Glass H & Poli L. Pharmaceutical Executive. January 2007.
Grant Budgeting and Negotiating in India and China. Jankosky J & Jiang Y & Farwell T. Applied Clinical Trials. November 2007.
Outlook for outsourcing. Glass H. Good Clinical Practice Journal. pp 21-24. November 2007.
The CRO Crop. Glass H & Beaudry D. Inside Outsourcing. November 2007.
Understanding Site Performance Differences in Multinational Phase III Clinical Trials. Glass H & DiFrancesco J. International Journal of Pharmaceutical Medicine. Vol 21, 2007.
Clinical grants: What is a fair market value? Glass H. Good Clinical Practice Journal. pp 23-25. August 2006.
The Marketplace for Clinical Grants. Glass H. Monitor. pp 69-74. October 2005.
Researchers as Marketers. Glass H. Successful Clinical Trials Management. pp 16-19. June 2004.
The Dual Role of Company Prescribing Loyalty in New Drug Launches. Glass H & Poli L. Journal of Pharmaceutical Marketing & Management. pp 47-62. Vol 16, July 2004.
Demographics, Practices, and Prescribing Characteristics of Physicians Who Are Early Adopters of New Drugs. Glass H & Rosenthal B. P&T. pp 2-8. Vol. 29, Iss. 11. November 2004.
Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Investigator Prescribing Behavior? Glass H. Disease Management. pp 77-87. Vol. 3, November 2004.
Physician Participation in Market Support Clinical Studies and Subsequent Prescribing Behavior. Glass H. Journal of Pharmaceutical Marketing & Management. pp 3-16. Vol. 15, May 2003.
Why Investigators Take Part in Clinical Trials. Glass H & Kane R. Applied Clinical Trials. Vol 9, June 2000.
Database Dynamics. Pierre J. & Brooks K. ICT, 2008.
Patterns in Prescribing Behavior: The Potential Hidden Costs of Using CROs. Glass H. Clinical and Non-Clinical Drug Development. pp 105-112.
 
 
 
TTC LLC Copyright 2011. All rights reserved.  Sitemap  |  

Clinical Trials

  |  Privacy Policy  
Share |